269 related articles for article (PubMed ID: 17927283)
1. Current management strategies for intraocular retinoblastoma.
Kim JW; Abramson DH; Dunkel IJ
Drugs; 2007; 67(15):2173-85. PubMed ID: 17927283
[TBL] [Abstract][Full Text] [Related]
2. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
Shields CL; Shields JA; Needle M; de Potter P; Kheterpal S; Hamada A; Meadows AT
Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
[TBL] [Abstract][Full Text] [Related]
3. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
4. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Singh A; Friedman DL; Naduvilath TJ
Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
[TBL] [Abstract][Full Text] [Related]
5. Chemoreduction in the management of retinoblastoma.
Shields JA; Shields CL; Meadows AT
Am J Ophthalmol; 2005 Sep; 140(3):505-6. PubMed ID: 16139001
[No Abstract] [Full Text] [Related]
6. Treatment of intraocular retinoblastoma with vincristine and carboplatin.
Rodriguez-Galindo C; Wilson MW; Haik BG; Merchant TE; Billups CA; Shah N; Cain A; Langston J; Lipson M; Kun LE; Pratt CB
J Clin Oncol; 2003 May; 21(10):2019-25. PubMed ID: 12743157
[TBL] [Abstract][Full Text] [Related]
7. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
Gündüz K; Shields CL; Shields JA; Meadows AT; Gross N; Cater J; Needle M
Arch Ophthalmol; 1998 Dec; 116(12):1613-7. PubMed ID: 9869790
[TBL] [Abstract][Full Text] [Related]
8. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
Zage PE; Reitman AJ; Seshadri R; Weinstein JL; Mets MB; Zeid JL; Greenwald MJ; Strauss LC; Goldman S
Pediatr Blood Cancer; 2008 Mar; 50(3):567-72. PubMed ID: 17729249
[TBL] [Abstract][Full Text] [Related]
10. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
11. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Trans Am Ophthalmol Soc; 2004; 102():35-44; discussion 44-5. PubMed ID: 15747743
[TBL] [Abstract][Full Text] [Related]
12. The International Classification of Retinoblastoma predicts chemoreduction success.
Shields CL; Mashayekhi A; Au AK; Czyz C; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2006 Dec; 113(12):2276-80. PubMed ID: 16996605
[TBL] [Abstract][Full Text] [Related]
13. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
14. A perspective on chemoreduction and focal therapy for retinoblastoma.
Balasubramanya R; Pushker N; Bajaj MS; Ghose S; Rani A
Am J Ophthalmol; 2002 Oct; 134(4):633; author reply 633-4. PubMed ID: 12383837
[No Abstract] [Full Text] [Related]
15. Chemotherapy plus local treatment in the management of intraocular retinoblastoma.
Murphree AL; Villablanca JG; Deegan WF; Sato JK; Malogolowkin M; Fisher A; Parker R; Reed E; Gomer CJ
Arch Ophthalmol; 1996 Nov; 114(11):1348-56. PubMed ID: 8906025
[TBL] [Abstract][Full Text] [Related]
16. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma.
Wilson MW; Haik BG; Liu T; Merchant TE; Rodriguez-Galindo C
Am J Ophthalmol; 2005 Sep; 140(3):397-406. PubMed ID: 16138999
[TBL] [Abstract][Full Text] [Related]
17. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.
Brichard B; De Bruycker JJ; De Potter P; Neven B; Vermylen C; Cornu G
Med Pediatr Oncol; 2002 Jun; 38(6):411-5. PubMed ID: 11984802
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic changes in retinoblastoma after chemoreduction.
Dithmar S; Aabert TM; Grossniklaus HE
Retina; 2000; 20(1):33-6. PubMed ID: 10696744
[TBL] [Abstract][Full Text] [Related]
19. Chemoreduction of Progressive Intraocular Retinoblastoma by Systemic Topotecan.
Sultan I; Hajja Y; Nawaiseh I; Mehyar M; Deebajah R; Jaradat I; Yousef YA
Ophthalmic Genet; 2016 Jun; 37(2):209-13. PubMed ID: 26760494
[TBL] [Abstract][Full Text] [Related]
20. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
